Search Results for "Parnate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Parnate. Results 1 to 6 of 6 total matches.
See also: tranylcypromine

Entacapone for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2000  (Issue 1070)
) or tranylcypromine (Parnate). Selegiline (Eldepryl), an antiparkinson drug that is a selective MAO inhibitor, can ...
Entacapone (Comtan), a catechol-O-methyltransferase (COMT) inhibitor, has been approved by the FDA for adjunctive use with levodopa/carbidopa in patients with Parkinson's disease who have end-of-dose "wearing off"symptoms.
Med Lett Drugs Ther. 2000 Jan 24;42(1070):7-8 |  Show IntroductionHide Introduction

Foods Interacting With MAO Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 1989  (Issue 785)
in the USA are the antidepressants tranylcypromine (Parnate), phenelzine (Nardil) and isocarboxazid (Marplan ...
Many fermented foods contain tyramine as a byproduct formed by the bacterial breakdown of the amino acid tyrosine; it can also be formed by para-hydroxylation of phenylethylamine or dehydroxylation of DOPA and dopamine. Tyramine and some other amines found in food can cause hypertensive reactions in patients taking monoamine oxidase (MAO)inhibitors.
Med Lett Drugs Ther. 1989 Feb 10;31(785):11-2 |  Show IntroductionHide Introduction

Fluoxetine (Prozac) Revisited

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 1990  (Issue 826)
), such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate; and others), has caused severe ...
In the short time since fluoxetine (Prozac - Lilly) first became available in the USA (Medical Letter, 30:45, 1988), it has become the most frequently prescribed of all antidepressants. Some recent reports, however, have questioned its safety.
Med Lett Drugs Ther. 1990 Sep 7;32(826):83-4 |  Show IntroductionHide Introduction

Transdermal Selegiline (Emsam)

   
The Medical Letter on Drugs and Therapeutics • May 22, 2006  (Issue 1235)
such as phenelzine (Nardil), tranylcypromine (Parnate) and isocarboxazid (Marplan) are nonselective and inhibit ...
The FDA recently approved the monoamine oxidase inhibitor (MAOI) selegiline in a transdermal (patch) formulation (Emsam - Bristol-Myers Squibb/Somerset) for treatment of major depressive disorder. Selegiline is also available in an oral formulation (Eldepryl, and others) for treatment of Parkinson's disease.
Med Lett Drugs Ther. 2006 May 22;48(1235):41-2 |  Show IntroductionHide Introduction

Drugs That Cause Sexual Dysfunction: An Update

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 1992  (Issue 876)
), and tranylcypromine (Parnate) frequently cause difficulty in ejaculation or anorgasmia. Clomipramine (Anafranil ...
Many commonly used drugs can interfere with sexual function in both men and women, causing loss of libido, interfering with erection or ejaculation in men, and delaying or preventing orgasm in women. Drug-related effects on sexual function may be difficult to distinguish from the effects of depression or disease, but most are reversible when drug use is stopped and sometimes when dosage is decreased. Since many patients are reluctant to talk about sexual difficulties, physicians may wish to ask about the possibility of drug-induced sexual dysfunction, particularly when they have...
Med Lett Drugs Ther. 1992 Aug 7;34(876):73-8 |  Show IntroductionHide Introduction

Drugs for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023  (Issue 1691)
mg/24 hr 2042.80 Tranylcypromine – generic 10 mg tabs 10 mg once/day 20-30 mg bid 127.10 Parnate ...
A selective serotonin reuptake inhibitor (SSRI) is generally used for initial treatment of major depressive disorder (MDD). A serotonin-norepinephrine reuptake inhibitor (SNRI), bupropion (Wellbutrin SR, and others), and mirtazapine (Remeron, and others) are reasonable alternatives. Improvement in symptoms can occur within the first two weeks of treatment with these drugs, but a substantial benefit may not be achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200   doi:10.58347/tml.2023.1691a |  Show IntroductionHide Introduction